Senhwa Biosciences Initiates Phase I/II Trial of Silmitasertib for Pediatric Solid Tumors
Key Insights
Senhwa Biosciences (search) has dosed the first patient in a Phase I/II trial evaluating silmitasertib plus chemotherapy for relapsed or refractory solid tumors in children and young adults.
The study will determine the recommended dosage and assess the tolerability, safety, and efficacy of silmitasertib, particularly in neuroblastoma (search) and sarcomas (search).
The trial, involving up to 114 participants, is being conducted across Beat Childhood Cancer Research Consortium member hospitals.
Senhwa Biosciences (search) has commenced a Phase I/II clinical trial at Penn State Health Children’s Hospital to investigate silmitasertib (CX-4945) in combination with chemotherapy for treating relapsed or refractory solid tumors in children and young adults. This study aims to establish the optimal dosage and evaluate the tolerability, safety, and efficacy of the treatment, with a focus on cancers such as neuroblastoma (search) and sarcomas (search).
The trial anticipates enrolling up to 114 participants through the Beat Childhood Cancer Research Consortium member hospitals. The study is designed to develop new therapeutic strategies by closely monitoring individual patient responses and the duration of disease control. Funding for the trial is provided by the Beat Childhood Cancer Foundation and the Little Warrior Foundation, with previous research supported by Four Diamonds.
Collaborative Effort and Therapeutic Potential
Senhwa Biosciences (search) CEO Jin-Ding Huang expressed enthusiasm for the collaboration with Penn State College of Medicine and the Beat Childhood Cancer Research Consortium. "We are greatly honoured to collaborate with the Penn State College of Medicine and Beat Childhood Cancer Research Consortium...and look forward to realising its therapeutic value in this urgently needed field for childhood cancers through this study."
Regulatory Designations and Unmet Needs
Silmitasertib has received several key designations from the U.S. Food and Drug Administration (FDA). Last month, it was granted orphan drug designation (ODD) for neuroblastoma (search) treatment. In September, it received a rare pediatric disease designation. The drug has also been designated for other indications, including medulloblastoma (search), biliary tract cancer (search), and cholangiocarcinoma (search).
Neuroblastoma (search), predominantly diagnosed in children under five, is characterized by a high rate of metastasis at the time of diagnosis. The 20-year survival rate for this aggressive cancer remains low, at approximately 30%, underscoring the urgent need for more effective treatments.